A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL

Trial Profile

A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Naltrexone (Primary) ; Buprenorphine
  • Indications Opioid abuse
  • Focus Registrational; Therapeutic Use
  • Sponsors Alkermes plc
  • Most Recent Events

    • 13 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 Nov 2015 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top